SCHEMBL4590472

SCHEMBL4590472

COc1cc(OC)cc(C2(O)C(=O)Nc3ccc(Cl)cc32)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.52
CDYL Q9Y232 2/20 0.52
IDO1 P14902 2/20 0.49
ADAMTS5 Q9UNA0 2/20 0.47
BRD4 O60885 4/20 0.47
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 2/20 0.43
MDM2 Q00987 2/20 0.43
CDYL2 Q8N8U2 1/20 0.42
CDY1; CDY1B Q9Y6F8 1/20 0.42
POLB P06746 1/20 0.40
CASP6 P55212 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3967434 0.89 TP53 (0.51) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL2498528 0.89 BRD4 (0.57) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL2499643 0.88 CDYL (0.60) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL4590436 0.82 ADAMTS5 (0.48) CBX7CDYLIDO1ADAMTS5TP53
SCHEMBL2495393 0.81 KMT2A (0.57) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL2497429 0.81 CBX7 (0.52) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL2889479 0.81 CBX7 (0.52) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL2497407 0.79 BRD4 (0.52) CBX7CDYLIDO1BRD4KMT2A
SCHEMBL3967991 0.78 ADAMTS5 (0.52) CBX7CDYLIDO1ADAMTS5BRD4
SCHEMBL2493174 0.78 KMT2A (0.55) CBX7CDYLIDO1ADAMTS5BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425566-B2 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2008-09-16 US disclosed
US-20050176770-A1 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2005-08-11 US disclosed
US-6864277-B2 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2005-03-08 US disclosed
US-20030162767-A1 With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin SANOFI-AVENTIS (FR) 2003-08-28 US disclosed
EP-1296976-A1 NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Sanofi-Aventis (FR) 2003-04-02 EP disclosed
WO-2001098295-A1 NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI-SYNTHELABO (FR) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162767-A1 With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin AVPR1B, AVPR1A, AVPR2 CBX7 4049/4885CDYL 4544/4885IDO1 2570/4885
US-20050176770-A1 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them AVPR1B, AVPR2, AVPR1A CBX7 3930/4885CDYL 3213/4885IDO1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.